

Comprehensive validation of fasting-based and oral glucose tolerance test-based indices of insulin secretion against gold standard measures

Katsiaryna Prystupa ^{1,2,3,4}, Rebecka Renklint,⁵ Youssef Chninou,⁵ Julia Otten,⁵ Louise Fritsche ^{3,4}, Sebastian Hoerber,^{3,4,6} Andreas Peter,^{3,4,6} Andreas L Birkenfeld ^{1,3,4}, Andreas Fritsche,^{1,3,4} Martin Heni ^{1,3,4,6,7}, Robert Wagner^{1,2,3,8}

To cite: Prystupa K, Renklint R, Chninou Y, *et al.* Comprehensive validation of fasting-based and oral glucose tolerance test-based indices of insulin secretion against gold standard measures. *BMJ Open Diab Res Care* 2022;**10**:e002909. doi:10.1136/bmjdr-2022-002909

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bmjdr-2022-002909>).

Received 22 April 2022
Accepted 12 August 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Katsiaryna Prystupa;
katsiaryna.prystupa@med.uni-tuebingen.de

ABSTRACT

Introduction With pre-diabetes and diabetes increasingly recognized as heterogeneous conditions, assessment of beta-cell function is gaining clinical importance to identify disease subphenotypes. Our study aims to comprehensively validate all types of surrogate indices based on oral glucose tolerance test (OGTT) and fasting measurements in comparison with gold standard methods.

Research design and methods The hyperglycemic clamp extended with glucagon-like peptide 1 (GLP-1) infusion and intravenous glucose tolerance test (IVGTT), as well as OGTT, was performed in two well-phenotyped cohorts. The gold standard-derived indices were compared with surrogate insulin secretion markers, derived from fasting state and OGTT, using both Pearson's and Spearman's correlation coefficients. The insulin-based and C-peptide-based indices were analyzed separately in different groups of glucose tolerance and the entire cohorts.

Results The highest correlation coefficients were found for area under curve (AUC) (I_{0-30})/AUC (G_{0-30}), I_{30}/G_{30} , first-phase Stumvoll and Kadowaki model. These indices have high correlation coefficients with measures obtained from both insulin and C-peptide levels from IVGTT and hyperglycemic clamp. AUC (I_{0-120})/AUC (G_{0-120}), BIGTT-AIR₀₋₆₀₋₁₂₀, I_{30}/G_{30} , first-phase Stumvoll and AUC (I_{0-30})/AUC (G_{0-30}) demonstrated the strongest association with incretin-stimulated insulin response.

Conclusions We have identified glucose-stimulated and GLP-1-stimulated insulin secretion indices, derived from OGTT and fasting state, that have the strongest correlation with gold standard measures and could be potentially used in future researches and clinical practice.

INTRODUCTION

Reduced sensitivity to the action of insulin and deficient insulin secretion are two physiological defects underlying type 2 diabetes (T2D) and impaired glucose tolerance (IGT).

Insulin secretion and sensitivity are associated across a negative feedback loop, in which

WHAT IS ALREADY KNOWN ON THIS TOPIC

- ⇒ Hyperglycemic clamp and intravenous glucose tolerance test (IVGTT) are considered gold standards to assess insulin secretion, but they are expensive and laborious.
- ⇒ Several fasting-derived and oral glucose tolerance test (OGTT)-derived indices have been proposed and separately evaluated, but large head-to-head studies validating them to gold standard measurements are still lacking.

WHAT THIS STUDY ADDS

- ⇒ Area under curve (AUC) (I_{0-30})/AUC (G_{0-30}), I_{30}/G_{30} , first-phase Stumvoll and Kadowaki model showed the highest correlation coefficients with the gold standard measures.
- ⇒ AUC (I_{0-120})/AUC (G_{0-120}), BIGTT-AIR₀₋₆₀₋₁₂₀, I_{30}/G_{30} , first-phase Stumvoll and AUC (I_{0-30})/AUC (G_{0-30}) are the most reliable measures for evaluating glucagon-like peptide 1-stimulated insulin release.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

- ⇒ The use of robust OGTT-based indices enables an accurate assessment of insulin secretion, also contributing to pre-diabetes subphenotyping, the prediction of type 2 diabetes and its complications.

beta-cells reimburse for changes in whole-body insulin sensitivity through a proportional and reciprocal increase in insulin secretion.¹

Insulin sensitivity and insulin secretion can be accurately determined by hyperinsulinemic-euglycemic and hyperglycemic clamps or intravenous glucose tolerance tests (IVGTTs) that are considered “gold standards” for these measurements.^{2,3} Precise assessment of these two traits is crucial to identify subphenotypes of pre-diabetes and T2D, which is gaining increasing importance

by acknowledgment of the pathophysiological heterogeneity of this condition.^{4,5} Furthermore, these measures can support the prediction of diabetes in non-diabetic subjects.^{6,7} However, the invasive, expensive, and time-consuming gold standard procedures are not applicable in routine clinical practice.

Several indices have been proposed to estimate insulin sensitivity and insulin secretion, based on more readily measurable parameters obtained in the fasting state or after an oral glucose tolerance test (OGTT).⁸ Their usefulness is influenced by the degree of correlation with gold standard indicators, by their reproducibility⁹ and by their ability to predict diabetes incidence similarly to more complex methods.^{10–12}

Many surrogate methods for insulin sensitivity assessment have been proposed and validated,^{10,12} but comprehensive studies to compare insulin secretion measures to gold standard methods are scarce. While several indices for beta-cell assessment based on dynamic changes in insulin and glucose during OGTT have been separately evaluated in numerous studies, most of these indices have not been compared head-to-head and there is still disagreement about their validity.^{13–15} Therefore, our work is aimed at performing a large, comprehensive comparative analysis of all types of indicators obtained in the fasting state or during OGTT to determine the secretion of insulin in comparison with the gold standards IVGTT and hyperglycemia clamp in two well-phenotyped cohorts. Moreover, the novel hyperglycemic clamp was used in one of our included trials¹⁶ allows for defining surrogate indices for glucagon-like peptide 1 (GLP1)–stimulated insulin secretion.

RESEARCH DESIGN AND METHODS

Participants

The 392 subjects included in the present analysis were part of the Tuebingen Family Study (TUEF), who were recruited based on their increased risk for T2D (prior gestational diabetes, overweight or positive family history). Three hundred and sixteen subjects participated in OGTT and IVGTT, and 76 in OGTT and hyperglycemic clamps. Informed written consent to the studies was obtained from all participants. The studies adhered to the Declaration of Helsinki. The study protocols were approved by the Ethical Committee of the Medical Faculty of the University of Tübingen (422/2002).

All participants were classified into different stages of glucose tolerance according to the revised WHO criteria.¹⁷ The IVGTT cohort consists of 209 subjects with normal glucose tolerance (NGT), 91 with impaired fasting glucose (IFG) and/or IGT, and 16 with test-diagnosed T2D (table 1).

Of the 91 subjects with IFG/IGT, 28 had isolated IFG (fasting plasma glucose 6.1–6.9 mmol/L), 40 had isolated IGT (2-hour glucose value 7.8–11.0 mmol/L), 23 had both IFG and IGT, and 16 had newly diagnosed T2D. The hyperglycemic clamp group comprises 49 NGT, 23

Table 1 Clinical and biochemical characteristics of the study population

Participated in OGTT and IVGTT	
n	316
Sex, male/female	183/133
Age (median (IQR))	47.00 (37.00–54.00)
BMI (median (IQR))	28.59 (25.11–32.20)
NGT (%)	209 (66.1%)
IFG and/or IGT	91 (28.8%)
Type 2 diabetes	16 (5.1%)
Participated in OGTT and hyperglycemic clamp	
n	76
Sex, male/female	33/43
Age (median (IQR))	36.00 (26.00–46.25)
BMI (median (IQR))	24.48 (22.01–26.94)
NGT	49 (64.5%)
IFG and/or IGT	23 (30.2%)
Type 2 diabetes	4 (5.3%)
BMI, body mass index; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; IVGTT, intravenous glucose tolerance test; NGT, normal glucose tolerance; OGTT, oral glucose tolerance test.	

pre-diabetes (IFG and/or IGT), and 4 screen-diagnosed T2D participants.

Procedures and calculations

In the IVGTT, an intravenous bolus injection of glucose was given (0.3 g/kg body weight in a 20% solution) at time 0 after baseline blood draw. Blood was sampled at 0, 2, 4, 6, 8, 10, 20, 30, 40, 50, and 60 min for measuring plasma glucose, insulin, and C-peptide (CP) concentration.¹⁸ The incremental area under curve (iAUC_{0–10}) for insulin and CP over the first 10 min of the test was determined using the trapezoidal method. Multivariate imputation by chained equations¹⁹ was performed for missingness, which was less than 2.6% and completely random.

The hyperglycemic clamp was performed as previously described.¹⁶ In brief, the clamp was initiated with a weight-adapted intravenous bolus of 20% glucose over 1 min and continued with an infusion of 20% glucose with periodic adjustments based on the negative feedback principle to maintain blood glucose at 10 mmol/L. After 120 min, GLP-1 was given as a bolus injection (4.5 pmol/kg), followed by continuous infusion of 1.5 pmol/kg/min during the next 60 min. Serum samples for insulin, CP, and glucose were drawn at –30 to –15, 0, 2.5, 5, 7.5, 10, 15, 30, 60, 90, 120, 140, 160, 170, and 180 min. Insulin secretion after an arginine bolus given at the end of the clamp was not analyzed in the current work. First phase of insulin release, reflecting the early insulin peak secreted from the pancreatic beta-cell in response to glucose stimulation, was calculated as the sum of insulin or CP

measurements at 2.5, 5, 7.5, and 10 min. The second phase of glucose-stimulated insulin release was derived as means of insulin or CP at 80, 100, and 120 min. GLP-1-stimulated insulin (CP) secretion at 10 mM glucose was assessed as a mean of 160, 170, and 180 min.

CP and insulin concentrations were determined using chemiluminescent methods on an ADVIA Centaur XPT analyzer (Siemens Healthineers, Eschborn, Germany). Glucose concentrations were measured using a hexokinase method on an ADVIA clinical chemistry XPT analyzer (Siemens Healthineers). The limits of quantification of the insulin and CP assays are 1 pmol/L and 16 pmol/L, respectively. Using quality control samples for the determination of assay imprecision, typical coefficients of variation were obtained: 4.6% (target concentration: 136 pmol/L) and 5.2% (597 pmol/L) using the insulin assay and 5.8% (337 pmol/L) and 6.2% (1470 pmol/L) using the CP assay.

All 392 persons participated in the OGTT, taking 75 g of glucose in a volume of 300 mL after an overnight fast. Samples for glucose and insulin measurements were taken at 0, 30, 60, and 120 min. Insulin secretion indices were calculated from these OGTTs.

The insulinogenic index (IGI), an index of beta-cell function, was computed as $(I_{30}-I_0)/(G_{30}-G_0)$, $(I_{60}-I_0)/(G_{60}-G_0)$, and $(I_{120}-I_0)/(G_{120}-G_0)$, with I_n , G_n , plasma concentrations at the nth minute for insulin and glucose, respectively.¹⁵

The beta-cell function insulin sensitivity glucose tolerance test (BIGTT) method is an estimation of an acute insulin response (AIR) derived from the following equation: $BIGTT-AIR_{0-30-120} = \exp[8.20 + (0.00178 \times I_0) + (0.00168 \times I_{30}) - (0.0000383 \times I_{120}) - (0.314 \times G_0) - (0.109 \times G_{30}) + (0.0781 \times G_{120}) + (0.180 \times \text{sex}) + (0.032 \times \text{BMI})]$, $BIGTT-AIR_{0-60-120} = \exp[8.20 + (0.00178 \times I_0) + (0.00168 \times I_{60}) - (0.0000383 \times I_{120}) - (0.314 \times G_0) - (0.109 \times G_{60}) + (0.0781 \times G_{120}) + (0.180 \times \text{sex}) + (0.032 \times \text{BMI})]$.²⁰

The ratio of the AUC for insulin and for CP to AUC for glucose over a specified time frame was calculated by applying the trapezoid rule (AUC (I_{all}), AUC (CP_{all}), AUC (I_{0-30})/AUC (G_{0-30}), AUC (CP₀₋₃₀)/AUC (G_{0-30}), AUC (CP₀₋₆₀)/AUC (G_{0-60}), AUC (I_{0-60})/AUC (G_{0-60}), AUC (I_{0-120})/AUC (G_{0-120}), AUC (CP₀₋₁₂₀)/AUC (G_{0-120})).¹⁴ The additional indices of insulin secretion used in this study were as follows: the corrected insulin response (CIR) = $I_{30}/(G_{30} \times (G_{30} - 3.89))$, $I_{60}/(G_{60} \times (G_{60} - 3.89))$, $I_{120}/(G_{120} \times (G_{120} - 3.89))$ ¹³; the insulin/glucose ratio derived as I_0/G_0 , I_{30}/G_{30} , I_{60}/G_{60} , and I_{120}/G_{120} , CP/glucose ratio CP_0/G_0 and CP_{120}/G_{120} , insulin and CP ratio at minute 30 (I_{30}/I_0 , CP_{30}/CP_0), minute 60 (I_{60}/I_0 , CP_{60}/CP_0) and at minute 120 (I_{120}/I_0 , CP_{120}/CP_0), delta insulin at 30 min $\Delta I_{30} = I_{30} - I_0$ and 60 min $\Delta I_{60} = I_{60} - I_0$, CP and insulin at fasting state (CP₀, I₀), minute 30 (CP₃₀, I₃₀), minute 60 (CP₆₀, I₆₀), and minute 120 (CP₁₂₀, I₁₂₀)^{13 21}; first-phase Stumvoll = $1283 + 1.829 \times I_{30} - 138.7 \times G_{30} + 3.772 \times I_0$; and second-phase Stumvoll = $286 + 0.416 \times I_{30} - 25.94 \times G_{30} + 0.926 \times I_0$ ¹¹; Kadowaki model = $(I_{30} - I_0)/(G_{30} - G_0)$ ²²; C-peptide index (CPI) $CPI_{120} = 100 \times C_{p120} (\text{ng/mL}) / G_{120} (\text{mg/dL})$,

$CPI_0 = 100 \times C_{p0} (\text{ng/mL}) / G_0 (\text{mg/dL})$ ²³; log-transformed insulin at minute 0, 30, 60, 90, 120 ($\log(I_0)$, $\log(I_{30})$, $\log(I_{60})$, $\log(I_{90})$, $\log(I_{120})$).²⁴

The Homeostasis Model Assessment (HOMA)–%B was calculated using the fasting plasma insulin and glucose concentration (HOMA–%B = $(20 \times I_0) / (G_0 - 3.5)$).²⁵

Fasting CP, insulin, and glucose levels were used in the homeostasis model assessment computer model to generate estimates of beta-cell function (HOMA2%B).²⁵

Statistical analysis

Statistical analyses were performed with R (software V.4.0.3).²⁶ Descriptive data are expressed as median ± IQRs. The relationship between the different estimates of insulin secretion was determined using both Pearson's and Spearman's correlation coefficients. The insulin and CP-derived insulin secretion indices were separately analyzed. The best-performing indices were selected according to Pearson's correlation coefficients, and a high correlation was defined as 0.6 or more. P values < 0.05 were considered statistically significant.

RESULTS

Our analysis included all participants of the TUEF study from whom hyperglycemic clamp or IVGTT and OGTT were available (n=392). We analyzed data from 316 persons (133 men and 183 women), who underwent IVGTTs and OGTTs, as well as 76 (33 men and 43 women) in whom hyperglycemic clamp and OGTT were performed. The characteristics of the study population are summarized in table 1.

Comparison of insulin secretion indices with dynamic insulin secretion measurements by IVGTT

The insulin secretion indices obtained from fasting or OGTT measurements were tested against IVGTT-obtained measurements (insulin iAUC₀₋₁₀ and CP iAUC₀₋₁₀) of beta-cell capacity.

The vast majority of tested surrogate insulin secretion indices except for CP₁₂₀/CP₀ and I₁₂₀/I₀ correlated significantly with first-phase insulin and CP-based IVGTT values in the group of NGT as well as in IFG and/or IGT group (online supplemental table 1). In NGT, the strongest correlation with first-phase insulin and CP by both Spearman's and Pearson's methods was found for CIR₃₀, I₃₀/G₃₀, BIGTT-AIR₀₋₃₀₋₁₂₀, first-phase Stumvoll, and AUC (I₀₋₃₀)/AUC (G₀₋₃₀) (online supplemental table 1).

In pre-diabetes, the strongest correlation between insulin iAUC₀₋₁₀ and CP iAUC₀₋₁₀ was identified for AUC (CP₀₋₆₀)/AUC (G₀₋₆₀), CP₃₀, CP₆₀/G₆₀, and CP₃₀/G₃₀ (online supplemental table 1).

The highest correlation in the entire cohort was detected for AUC (I₀₋₃₀)/AUC (G₀₋₃₀), first-phase Stumvoll, Kadowaki model, IGI₃₀, CIR₃₀, and I₃₀/G₃₀. The weakest correlation for both groups had CIR₁₂₀ and IGI₁₂₀.

We also analyzed the correlation coefficients in a group of participants with test-diagnosed T2D (n=16). According to our analysis, CP₃₀/CP₀, CP₆₀/CP₀, CIR₃₀, I₃₀/

I_0 , and BIGTT-AIR₀₋₃₀₋₁₂₀ correlated significantly with both insulin iAUC₀₋₁₀ and CP iAUC₀₋₁₀ (online supplemental table 1).

Comparison of insulin secretion indices with dynamic insulin secretion measurements in the hyperglycemic clamp

We tested different formulas for calculating insulin secretion from OGTT and hyperglycemic clamp techniques.

An overwhelming majority of surrogate indices have a positive correlation with the first-phase insulin response obtained from the gold standard in participants with NGT as well as with IFG or glucose tolerance (online supplemental table 2). In NGT, the numerically highest significant correlation with clamp-derived first-phase insulin secretion measured by insulin and CP was detected for AUC (I_{0-30})/AUC (G_{0-30}), I_{30} , I_{30}/G_{30} , and BIGTT-AIR₀₋₃₀₋₁₂₀ (online supplemental table 2).

According to both correlation coefficients, the strongest relationship between first-phase clamp-derived and OGTT-derived measurements in IFG/IGT group correspond to AUC (I_{0-30})/AUC (G_{0-30}), I_{30}/G_{30} , BIGTT-AIR₀₋₃₀₋₁₂₀, and Kadowaki model (online supplemental table 2).

The second-phase insulin and CP strongly correlate with AUC (I_{0-30})/AUC (G_{0-30}), AUC (I_{0-120})/AUC (G_{0-120}), I_{30} , I_{30}/G_{30} , BIGTT-AIR₀₋₃₀₋₁₂₀ in NGT (online supplemental table 2) and with I_0/G_0 , AUC (I_{0-30})/AUC (G_{0-30}), BIGTT-AIR₀₋₃₀₋₁₂₀, I_{30}/G_{30} , first-phase Stumvoll in pre-diabetes (online supplemental table 2).

The highest correlation coefficients with first-phase and second-phase insulin secretion are shown by AUC (I_{0-30})/AUC (G_{0-30}), BIGTT-AIR₀₋₃₀₋₁₂₀, I_{30}/G_{30} , I_{30} , and first-phase Stumvoll. The surrogate measures with the lowest correlation are CP₁₂₀, log(I_{120}) and log(I_{90}).

Due to the small number of participants with test-diagnosed T2D (n=4), they were excluded from this analysis.

Comparison of surrogate indices measuring insulin secretion using OGTT with the gold standard criteria revealed three indices (I_{30}/G_{30} , AUC (I_{0-30})/AUC (G_{0-30}), first-phase Stumvoll, and Kadowaki model) with the highest Pearson's and Spearman's coefficients for both groups (NGT and pre-diabetes) in two phases and during all tests (figure 1). However, the CIR₁₂₀ and IGI₁₂₀ are the overall indices with the lowest significant correlation compared with the insulin and CP gold standard measurements according to both correlations' methods in the groups.

GLP-1-induced insulin (C-peptide) secretion

Using data from the modified hyperglycemic clamp, with a GLP-1 infusion phase,¹⁶ we also tested the relationship between GLP-1-stimulated insulin release and OGTT-derived measurements. The vast majority of indices in NGT and pre-diabetes correlate significantly with clamp-derived GLP1-stimulated insulin secretion index. The strongest correlation belongs to I_{30}/G_{30} , first-phase Stumvoll, AUC (I_{0-120})/AUC (G_{0-120}), AUC (I_{0-30})/AUC (G_{0-30}),




Figure 1 Indices with the highest Spearman's and Pearson's correlation coefficients in pre-diabetes and NGT groups in both study cohorts. HC, hyperglycemic clamp; iAUC, incremental area under curve; IVGTT, intravenous glucose tolerance test; NGT, normal glucose tolerance.

and BIGTT-AIR₀₋₆₀₋₁₂₀ (figure 2). The weakest correlation coefficients have CIR₁₂₀ and CPI₁₂₀.

DISCUSSION

In this study, we compared fasting-based and/or OGTT-based insulin secretion markers to gold-standard measurements. Our study revealed that most surrogate indices of insulin secretion correlated significantly with dynamic measurements assessed from IVGTT and hyperglycemic clamp. The substantial difference between Pearson's and Spearman's correlation coefficients for some surrogate indices can be attributed to variables with skewed distributions.

The overall highest correlation coefficients calculated by both Pearson's and Spearman's tests were found for AUC (I_{0-30})/AUC (G_{0-30}), I_{30}/G_{30} , first-phase Stumvoll, and Kadowaki model. These indices have high correlation coefficients with gold standard measures, obtained both from insulin and CP measurements, both with IVGTT and hyperglycemic clamp. All four indices reflect insulin release and comprise OGTT-derived insulin and glucose levels at minutes 0 and 30 and predict insulin secretion abnormalities better than 120-min-based indices (eg, CP₁₂₀, CIR₁₂₀, and IGI₁₂₀). The somewhat weaker correlation with 120-min indices can probably be due to the changes in the incretin axis caused by oral intake of glucose.²⁷ Our findings are consistent with previously




Figure 2 Top indices by Spearman's and Pearson's correlation coefficients in a group of 76 participants compared with GLP-1-stimulated insulin secretion during hyperglycemic clamp. AIR, acute insulin response; AUC, area under curve; BIGTT, beta-cell function insulin sensitivity glucose tolerance test; GLP-1, glucagon-like peptide 1.

published results from numerous studies that include these indices.^{11 14 20 22 28}

The high correlation of AUC (I₀₋₁₂₀)/AUC (G₀₋₁₂₀) and BIGTT-AIR₀₋₆₀₋₁₂₀ with GLP-1-stimulated insulin secretion in our analysis argues for a longer assessment during OGTT when addressing incretin effects. The strong relationship between incretin-stimulated response and AUC (I₀₋₃₀)/AUC (G₀₋₃₀), I₃₀/G₃₀, first-phase Stumvoll in all experiments stresses the robustness of these surrogate indices to estimate insulin secretion. Another possible contributor to a comparably better correlation of short-term insulin/CP assessment during OGTT with gold standard measures could be a diverging influence of insulin clearance over time.⁹

Parenteral and oral glucose loading leads to the stimulation of glucose with the involvement of various physiological processes. Oral glucose ingestion activates complex mechanisms, including an incretin-related cascade and even the brain²⁹ that all in concert control insulin release.

The correlation between gold standard measures and insulin-based indices was higher than with CP-based indices. This is consistent with previous results.¹⁵ CP is considered to better reflect insulin release,^{30 31} but the vast majority of previously studied surrogate indices are based on measuring insulin. Due to a long half-life of CP (20–30 min), each measurement integrates insulin release from a more extensive time period, which not necessarily captures the aimed stimulated time frame.^{15 25 32}

One limitation of this work arises from the lack of ethnic heterogeneity in studied population. The investigated measures may not necessarily work similarly well in other ethnicities such as persons of Asian origin, who often have lower beta-cell function,³³ or persons of African origin, showing beta-cell hyper-responsiveness and decreased insulin clearance.³⁴

Taken together, we here determined which indices can most reliably estimate insulin secretion from fasting measures or OGTT. Given the importance of assessing

insulin secretion for the classification of patients in novel subgroups of pre-diabetes⁵ and diabetes,⁴ also for potential therapeutic considerations,³⁵ selection of appropriate estimates from OGTTs is crucial in research and could also play a role in future clinical practice.

Author affiliations

- ¹Department of Internal Medicine IV, Division of Diabetology, Endocrinology and Nephrology, Eberhard Karls Universität Tübingen, Tübingen, Germany
- ²Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany
- ³German Center for Diabetes Research (DZD), Neuherberg, Germany
- ⁴Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany
- ⁵Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden
- ⁶Institute for Clinical Chemistry and Pathobiochemistry, Department for Diagnostic Laboratory Medicine, University Hospital of Tübingen, Tübingen, Germany
- ⁷Division of Endocrinology and Diabetology, Department of Internal Medicine I, Ulm University Hospital, Ulm, Germany
- ⁸Medical Faculty, Department of Endocrinology and Diabetology, Heinrich Heine University, Düsseldorf, Germany

Acknowledgements We thank all the volunteers of the study for their participation. We acknowledge support from the Helmholtz Center Munich, Deutsche Forschungsgemeinschaft, the German Center for Diabetes Research (DZD e.V.), and the Open Access Publishing Foundation of the University of Tübingen.

Contributors KP, RW, and MH designed the analysis strategy, supervised the project, wrote the manuscript and are responsible for the overall content as guarantors. RR, YC, JO, ALB, AP, and AF contributed to the interpretation of the data and edited the manuscript.

Funding This work was supported in part by Grant 01GI0925 from the German Federal Ministry of Education and Research (BMBF) to the German Center for Diabetes Research (DZD).

Competing interests Outside of the current work, RW does report lecture fees from Novo Nordisk and Sanofi. He served on the advisory board of Akcea Therapeutics, Daiichi Sankyo, Sanofi, and Novo Nordisk. Outside of the current work, AF reports lecture fees and advisory board membership from Sanofi, Novo Nordisk, Eli Lilly, and AstraZeneca. Outside of the current work, MH reports research grants from Boehringer Ingelheim and Sanofi (both to the University Hospital of Tübingen), advisory board for Boehringer Ingelheim, and lecture fees from Boehringer Ingelheim, Sanofi, Novo Nordisk, Eli Lilly, and Merck Sharp & Dohme.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was approved by the Ethical Committee of the Medical Faculty of the University of Tübingen (422/2002). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. The data are not publicly available due to them containing information that could compromise research participant privacy/consent and may be made available upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given,

and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

ORCID iDs

Katsiaryna Prystupa <http://orcid.org/0000-0003-3368-1028>
 Louise Fritsche <http://orcid.org/0000-0003-0644-6161>
 Andreas L Birkenfeld <http://orcid.org/0000-0003-1407-9023>
 Martin Heni <http://orcid.org/0000-0002-8462-3832>

REFERENCES

- Stumvoll M, Gerich J. Clinical features of insulin resistance and beta cell dysfunction and the relationship to type 2 diabetes. *Clin Lab Med* 2001;21:31–51.
- DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. *Am J Physiol* 1979;237:E214.
- Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. *Endocr Rev* 1985;6:45–86.
- Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. *Lancet Diabetes Endocrinol* 2018;6:361–9.
- Wagner R, Heni M, Tabák AG, et al. Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. *Nat Med* 2021;27:49–57.
- Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. *Diabetologia* 2001;44:929–45.
- Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. prospective studies of Pima Indians. *N Engl J Med* 1993;329:1988–92.
- Lorenzo C, Wagenknecht LE, Rewers MJ, et al. Disposition index, glucose effectiveness, and conversion to type 2 diabetes: the insulin resistance atherosclerosis study (IRAS). *Diabetes Care* 2010;33:2098–103.
- Hudak S, Huber P, Lamprinou A, et al. Reproducibility and discrimination of different indices of insulin sensitivity and insulin secretion. *PLoS One* 2021;16:e0258476.
- Mari A, Pacini G, Murphy E, et al. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. *Diabetes Care* 2001;24:539–48.
- Stumvoll M, Mitrakou A, Pimenta W, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. *Diabetes Care* 2000;23:295–301.
- Otten J, Ahrén B, Olsson T. Surrogate measures of insulin sensitivity vs the hyperinsulinaemic-euglycaemic clamp: a meta-analysis. *Diabetologia* 2014;57:1781–8.
- Hanson RL, Pratley RE, Bogardus C, et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. *Am J Epidemiol* 2000;151:190–8.
- Retnakaran R, Shen S, Hanley AJ, et al. Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. *Obesity* 2008;16:1901–7.
- Tura A, Kautzky-Willer A, Pacini G. Insulinogenic indices from insulin and C-peptide: comparison of beta-cell function from OGTT and IVGTT. *Diabetes Res Clin Pract* 2006;72:298–301.
- Fritsche A, Stefan N, Hardt E, et al. A novel hyperglycaemic clamp for characterization of islet function in humans: assessment of three different secretagogues, maximal insulin response and reproducibility. *Eur J Clin Invest* 2000;30:411–8.
- Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a who consultation. *Diabet Med* 1998;15:539–53.
- Staiger H, Machicao F, Stefan N, et al. Polymorphisms within novel risk loci for type 2 diabetes determine beta-cell function. *PLoS One* 2007;2:e832.
- Azur MJ, Stuart EA, Frangakis C, et al. Multiple imputation by chained equations: what is it and how does it work? *Int J Methods Psychiatr Res* 2011;20:40–9.
- Hansen T, Drivsholm T, Urhammer SA, et al. The BIGTT test: a novel test for simultaneous measurement of pancreatic beta-cell function, insulin sensitivity, and glucose tolerance. *Diabetes Care* 2007;30:432–62.
- den Biggelaar LJCJ, Sep SJS, Eussen SJPM, et al. Discriminatory ability of simple OGTT-based beta cell function indices for prediction of prediabetes and type 2 diabetes: the CODAM study. *Diabetologia* 2017;60:432–41.
- Kadowaki T, Miyake Y, Hagura R, et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. *Diabetologia* 1984;26:44–9.
- Zhang H, Bian B, Hu F, et al. OGTT 1h serum C-peptide to plasma glucose concentration ratio is more related to beta cell function and diabetes mellitus. *Oncotarget* 2017;8:51786–91.
- Sun M, Huang X, Jiang L, et al. Characterization of β -cell function and insulin resistance in overweight Chinese adolescents with normal glucose tolerance. *Exp Ther Med* 2013;6:547–51.
- Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. *Diabetes Care* 2004;27:1487–95.
- R Core Team. R: a language and environment for statistical computing. Vienna, Austria R Foundation for Statistical Computing; 2020. <https://www.r-project.org>
<https://www.r-project.org>
- Herzberg-Schäfer SA, Staiger H, Heni M, et al. Evaluation of fasting state-/oral glucose tolerance test-derived measures of insulin release for the detection of genetically impaired β -cell function. *PLoS One* 2010;5:e14194.
- Stumvoll M, Van Haefen T, Fritsche A, et al. Oral glucose tolerance test indexes for insulin sensitivity and secretion based on various availabilities of sampling times. *Diabetes Care* 2001;24:796–7.
- Heni M, Wagner R, Willmann C, et al. Insulin action in the hypothalamus increases second-phase insulin secretion in humans. *Neuroendocrinology* 2020;110:929–37.
- Saisho Y. Postprandial C-peptide to glucose ratio as a marker of β cell function: implication for the management of type 2 diabetes. *Int J Mol Sci* 2016;17:744.
- Leighton E, Sainsbury CA, Jones GC. A practical review of C-peptide testing in diabetes. *Diabetes Ther* 2017;8:475–87.
- Marques RG, Fontaine MJ, Rogers J. C-Peptide: much more than a byproduct of insulin biosynthesis. *Pancreas* 2004;29:231–8.
- Gujral UP, Narayan KMV, Kahn SE, et al. The relative associations of β -cell function and insulin sensitivity with glycemic status and incident glycemic progression in migrant Asian Indians in the United States: the MASALA study. *J Diabetes Complications* 2014;28:45–50.
- Armiyaw L, Sarcone C, Fosam A, et al. Increased β -cell responsivity independent of insulin sensitivity in healthy African American adults. *J Clin Endocrinol Metab* 2020;105:e2429–38.
- Fritsche A, Heni M, Peter A, et al. Considering insulin secretory capacity as measured by a fasting C-Peptide/Glucose ratio in selecting glucose-lowering medications. *Exp Clin Endocrinol Diabetes* 2022;130:200–4.